首页> 外文期刊>World Journal of Gastroenterology >Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis.
【24h】

Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis.

机译:益生菌唾液乳杆菌的预防作用。唾液,在大鼠结肠炎的TNBS模型中。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To investigate the intestinal anti-inflammatory effect and mechanism of a probiotic Lactobacillus salivarius ssp. salivarius CECT5713 in the TNBS model of rat colitis. METHODS: Female Wistar rats (180-200 g) were used in this study. A group of rats were administered orally the probiotic L. salivarius ssp. salivarius (5X10(8) CFU suspended in 0.5 mL of skimmed milk) daily for 3 wk. Two additional groups were used for reference, a non-colitic and a control colitic without probiotic treatment, which received orally the vehicle used to administer the probiotic. Two weeks after starting the experiment, the rats were rendered colitic by intracolonic administration of 10 mg of TNBS dissolved in 0.25 mL of 500 mL/L ethanol. One week after colitis induction, all animals were killed and colonic damage was evaluated both histologically and biochemically. The biochemical studies performed in colonic homogenates include determination of myeloperoxidase (MPO) activity, glutathione (GSH) content, leukotriene B(4) (LTB(4)) and tumor necrosis factor alpha (TNF-alpha) levels, as well as inducible nitric oxide synthase (iNOS) expression. In addition, the luminal contents obtained from colonic samples were used for microbiological studies, in order to determine Lactobacilli and Bifidobacteria counts. RESULTS: Treatment of colitic rats with L. salivarius ssp. salivarius resulted in amelioration of the inflammatory response in colitic rats, when compared with the corresponding control group without probiotic treatment. This anti-inflammatory effect was evidenced macroscopically by a significant reduction in the extent of colonic necrosis and/or inflammation induced by the administration of TNBS/ethanol (2.3+/-0.4 cm vs 3.4+/-0.3 cm in control group, P<0.01) and histologically by improvement of the colonic architecture associated with a reduction in the neutrophil infiltrate in comparison with non-treated colitic rats. The latter was confirmed biochemically by a significant reduction of colonic MPO activity (105.3+/-26.0U/g vs 180.6+/-21.9 U/g, P<0.05), a marker of neutrophil infiltration. The beneficial effect was associated with an increase of the colonic GSH content (1 252+/-42 nmol/g vs 1 087+/-51 nmol/g, P<0.05), which is depleted in colitic rats, as a consequence of the oxidative stress induced by the inflammatory process. In addition, the treatment of colitic rats with L. salivarius resulted in a significant reduction of colonic TNF-alpha levels (509.4+/-68.2 pg/g vs 782.9+/-60.1 pg/g, P<0.01) and in a lower colonic iNOS expression, when compared to TNBS control animals without probiotic administration. Finally, treated colitic rats showed higher counts of Lactobacilli species in colonic contents than control colitic rats, whereas no differences were observed in Bifidobacteria counts. CONCLUSION: Administration of the probiotic L. salivarius ssp. salivarius CECT5713 facilitates the recovery of the inflamed tissue in the TNBS model of rat colitis, an effect associated with amelioration of the production of some of the mediators involved in the inflammatory response in the intestine, such as cytokines, including TNF-alpha and NO. This beneficial effect could be ascribed to its effect on the altered immune response that occurs in this inflammatory condition.
机译:目的:探讨益生菌唾液乳杆菌ssp的肠道抗炎作用及其机理。大鼠结肠炎TNBS模型中的唾液CECT5713。方法:本研究使用雌性Wistar大鼠(180-200 g)。一组大鼠口服益生菌唾液乳杆菌ssp。唾液(5X10(8)CFU悬浮在0.5 mL脱脂牛奶中)每天3周。另外两个组用作参考,非结肠炎性和未经益生菌处理的对照结肠炎,它们口服接受用于施用益生菌的载体。实验开始两周后,通过结肠内给药10 mg溶于0.25 mL 500 mL / L乙醇的TNBS,使大鼠变为结肠炎。诱导结肠炎后一周,杀死所有动物,并从组织学和生化方面评估结肠损伤。在结肠匀浆中进行的生化研究包括确定髓过氧化物酶(MPO)活性,谷胱甘肽(GSH)含量,白三烯B(4)(LTB(4))和肿瘤坏死因子α(TNF-alpha)水平以及诱导型硝酸氧化物合酶(iNOS)的表达。另外,将从结肠样品中获得的腔内物质用于微生物学研究,以确定乳杆菌和双歧杆菌计数。结果:唾液乳杆菌对结肠炎大鼠的治疗。与没有进行益生菌治疗的相应对照组相比,唾液能改善结肠炎大鼠的炎症反应。宏观上,这种抗炎作用是通过TNBS /乙醇给药引起的结肠坏死和/或炎症程度的显着降低来证实的(对照组为2.3 +/- 0.4 cm,而对照组为3.4 +/- 0.3 cm,P <与未经治疗的结肠炎大鼠相比,通过结肠结构的改善与中性粒细胞浸润的减少相关的组织学上的差异(0.01)。后者通过结肠中性粒细胞浸润的标志物结肠MPO活性的明显降低(105.3 +/- 26.0U / g对180.6 +/- 21.9 U / g,P <0.05)得到了生化证实。有益的作用与结肠GSH含量的增加有关(1252 +/- 42 nmol / g对1 087 +/- 51 nmol / g,P <0.05),这是由于在结肠炎大鼠中耗尽由炎症过程引起的氧化应激。此外,用唾液乳杆菌治疗结肠炎大鼠可显着降低结肠TNF-α水平(509.4 +/- 68.2 pg / g与782.9 +/- 60.1 pg / g,P <0.01),并降低与未施用益生菌的TNBS对照动物相比,结肠iNOS的表达。最后,处理过的结肠炎大鼠结肠中的乳酸杆菌菌种计数高于对照结肠炎大鼠,而双歧杆菌计数未见差异。结论:益生菌唾液乳杆菌ssp的施用。唾液CECT5713促进了大鼠结肠炎TNBS模型中发炎组织的恢复,这是与肠中某些参与炎症反应的介质(例如包括TNF-α和NO在内的细胞因子)的产生有关的影响。这种有益作用可以归因于其对在这种炎症条件下发生的免疫应答改变的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号